Mihir Shah, MD
Surgical Oncology · Washington, DCNPI 1063701746
Payments from drug & device makers
What this record shows
This record is dominated by education: $70,000 of the $84,157 with a category attached, or 83.2%. Intuitive Surgical accounts for 99.7% of it on its own, with 3 other manufacturers making up the rest.
Across 96 payments — averaging $876.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$84K
- Medtronic$127
- Ipsen Biopharmaceuticals, Inc$70
- Johnson & Johnson$30
Across 1 payment — averaging $16,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gunze Limited$16K
What the payments were for
- Travel & lodging$9,67311%
- Food & beverage$4,4845%
- Education$70,00083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 91 | $83,930 |
| Medtronic | 1 | $127 |
| Ipsen Biopharmaceuticals, Inc | 3 | $70 |
| Johnson & Johnson | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$83,159
- Signia$127
How this compares
Too few surgical oncology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 11 | $26,943 |
| EliquisApixaban | 17 | $7,719 |
| Pantoprazole Sodium | 32 | $392 |
| Gabapentin | 17 | $182 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Washington
- Wayne FrederickWashington$832K
- Danier MooreWashington$2K
- Bonnie SunWashington$2K
- Robin WilliamsWashington$1K
- Waddah Al-RefaieWashington$1K
- Victor GallWashington$598
- Quyen ChuWashington$442
- Joyce WongWashington$315
- Jeffrey PeltonWashington$276
- Mark StevesWashington$219
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.